Pharmaceuticals has made over 1 trades of the Avenue Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals sold 388,888 units of ATXI stock worth $2,998,326 on 11 October 2022.
The largest trade Pharmaceuticals's ever made was selling 388,888 units of Avenue Therapeutics Inc stock on 11 October 2022 worth over $2,998,326. On average, Pharmaceuticals trades about 388,888 units every 0 days since 2022.
You can see the complete history of Pharmaceuticals Gen stock trades at the bottom of the page.
Pharmaceuticals's mailing address filed with the SEC is 7, Oser Avenue, Hauppauge, Town of Smithtown, Suffolk County, New York, 11788, United States.
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss et Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include: